Plain-English translation of NCT07025889 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new medication designed to target a specific protein found on stomach cancer cells. You would receive combined with (an immunotherapy drug) and chemotherapy drugs ( and ) as your first treatment for advanced stomach cancer. The study is designed to find the safest and most effective dose, and to see how well this three-drug combination works together.
Advanced stomach cancer is difficult to treat, and patients need new options beyond standard chemotherapy alone. This treatment combines different approaches — targeting a specific cancer protein, boosting the immune system, and chemotherapy — to see if working together they can help patients live longer and better.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital regularly to receive the three-drug treatment combination through infusions and oral medications as part of a structured treatment schedule. The study has two phases: first, doctors will determine the safest dose by treating a small group of patients, then they will enroll more patients to confirm safety and measure how well the treatment works. You would have blood tests, scans, and other monitoring to check how you're responding and to watch for side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Ruijin Hospital
Collaborators
Shanghai Jiao Tong University School of Medicine
Enrollment target
~55 participants
Started
June 2025
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ruijin Hospital, Shanghai Jiao Tong University School of Medic
Ruijin Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.